Literature DB >> 18381816

An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization.

Bing Xie1, Jikui Shen, Aling Dong, Mara Swaim, Sean F Hackett, Lorenza Wyder, Susanne Worpenberg, Samuel Barbieri, Peter A Campochiaro.   

Abstract

Proteins with a disintegrin and a metalloproteinase domain (ADAMs) are a family of membrane-bound proteinases that bind integrins through their disintegrin domain. In this study, we have found modest expression of ADAM15 in pericytes in normal retina and strong up-regulation of ADAM15 in retinal vascular endothelial cells in ischemic retina. Increased expression of vascular endothelial growth factor (VEGF) in the retina in the absence of ischemia also increased ADAM15 levels, and knockdown of Vegf mRNA in ischemic retina reduced Adam15 mRNA. Mice deficient in ADAM15 showed a significant reduction in ischemia-induced retinal neovascularization, choroidal neovascularization at rupture sites in Bruch's membrane, and VEGF-induced subretinal neovascularization. ADAM15-deficient mice also showed reduced levels of VEGF(164), VEGF receptor 1, and VEGF receptor 2 in ischemic retina. These data suggest that ADAM15 and VEGF participate in an amplification loop; VEGF increases expression of ADAM15, which in turn increases expression of VEGF and its receptors. Perturbation of the loop by elimination of ADAM15 suppresses ocular neovascularization in 3 different model systems, and thus ADAM15 provides a new therapeutic target for diseases complicated by neovascularization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381816      PMCID: PMC2493454          DOI: 10.1096/fj.07-099283

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  35 in total

Review 1.  Shedding light on ADAM metalloproteinases.

Authors:  Ari-Pekka J Huovila; Anthony J Turner; Markku Pelto-Huikko; Iivari Kärkkäinen; Rebekka M Ortiz
Journal:  Trends Biochem Sci       Date:  2005-07       Impact factor: 13.807

2.  Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model.

Authors:  J Luna; T Tobe; S A Mousa; T M Reilly; P A Campochiaro
Journal:  Lab Invest       Date:  1996-10       Impact factor: 5.662

3.  Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia.

Authors:  H P Gerber; F Condorelli; J Park; N Ferrara
Journal:  J Biol Chem       Date:  1997-09-19       Impact factor: 5.157

4.  HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.

Authors:  Michael J Gray; Jing Zhang; Lee M Ellis; Gregg L Semenza; Douglas B Evans; Stephanie S Watowich; Gary E Gallick
Journal:  Oncogene       Date:  2005-04-28       Impact factor: 9.867

5.  Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase.

Authors:  R Y Fleming; L M Ellis; N U Parikh; W Liu; C A Staley; G E Gallick
Journal:  Surgery       Date:  1997-08       Impact factor: 3.982

6.  Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases.

Authors:  Nor Eddine Sounni; Christian Roghi; Vincent Chabottaux; Mathias Janssen; Carine Munaut; Erik Maquoi; Beatriz G Galvez; Christine Gilles; Francis Frankenne; Gillian Murphy; Jean-Michel Foidart; Agnès Noel
Journal:  J Biol Chem       Date:  2004-01-16       Impact factor: 5.157

7.  Oxygen-induced retinopathy in the mouse.

Authors:  L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-01       Impact factor: 4.799

8.  Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model.

Authors:  T Tobe; S Ortega; J D Luna; H Ozaki; N Okamoto; N L Derevjanik; S A Vinores; C Basilico; P A Campochiaro
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

9.  Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3.

Authors:  W Brian Saunders; Brenda L Bohnsack; Jennifer B Faske; Nicholas J Anthis; Kayla J Bayless; Karen K Hirschi; George E Davis
Journal:  J Cell Biol       Date:  2006-10-09       Impact factor: 10.539

10.  Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells.

Authors:  D Nath; P M Slocombe; P E Stephens; A Warn; G R Hutchinson; K M Yamada; A J Docherty; G Murphy
Journal:  J Cell Sci       Date:  1999-02       Impact factor: 5.285

View more
  13 in total

Review 1.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

2.  Agents that bind annexin A2 suppress ocular neovascularization.

Authors:  Raquel Lima e Silva; Jikui Shen; Yuan Yuan Gong; Christopher P Seidel; Sean F Hackett; Kamala Kesavan; Douglas B Jacoby; Peter A Campochiaro
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

Review 3.  A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease.

Authors:  Sheng Zhong; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2019-03-21       Impact factor: 5.858

4.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

5.  ADAM9 is involved in pathological retinal neovascularization.

Authors:  Victor Guaiquil; Steven Swendeman; Tsunehiko Yoshida; Sai Chavala; Peter A Campochiaro; Carl P Blobel
Journal:  Mol Cell Biol       Date:  2009-03-09       Impact factor: 4.272

6.  Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF.

Authors:  Jikui Shen; David F Choy; Tsunehiko Yoshida; Takeshi Iwase; Gulnar Hafiz; Bing Xie; Sean F Hackett; Joseph R Arron; Peter A Campochiaro
Journal:  J Cell Physiol       Date:  2014-08       Impact factor: 6.384

7.  Characterization of oxygen-induced retinopathy in mice carrying an inactivating point mutation in the catalytic site of ADAM15.

Authors:  Thorsten Maretzky; Carl P Blobel; Victor Guaiquil
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-23       Impact factor: 4.799

Review 8.  Contribution of ADAM17 and related ADAMs in cardiovascular diseases.

Authors:  Tatsuo Kawai; Katherine J Elliott; Rosario Scalia; Satoru Eguchi
Journal:  Cell Mol Life Sci       Date:  2021-02-11       Impact factor: 9.207

9.  MicroRNA-147b regulates vascular endothelial barrier function by targeting ADAM15 expression.

Authors:  Victor Chatterjee; Richard S Beard; Jason J Reynolds; Ricci Haines; Mingzhang Guo; Matthew Rubin; Jenny Guido; Mack H Wu; Sarah Y Yuan
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

10.  Gene hunting of the Genetic Analysis Workshop 16 rheumatoid arthritis data using rough set theory.

Authors:  Chatchawit Aporntewan; David H Ballard; Ji Young Lee; Joon Sang Lee; Zheyang Wu; Hongyu Zhao
Journal:  BMC Proc       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.